Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma, according to an article published in the Journal of Clinical Oncology.1
Researchers analyzed data from 3 prospective trials containing baseline data of 185 enrolled patients receiving immunochemotherapy. The median age of enrolled patients was 55 years; 92% had stage III or IV follicular lymphoma.
Five-year overall progression-free survival was 55%; overall survival was 92%. Survival was inferior for patients with a total metabolic tumor volume of greater than 510 cm3; the 29% of patients in this group had a 5-year progression-free survival of 33%, and a 5-year overall survival of 85%.
The authors conclude that baseline total metabolic tumor volume is a strong independent prognostic tool, though if used in conjunction with the Follicular Lymphoma International Prognostic Index, patients at high risk of early progression can be identified.
- Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a tooled analysis of three multicenter studies. J Clin Oncol. 2016 Aug 22. doi: 10.1200/JCO.2016.66.9440 [Epub ahead of print]